

HB-200 Data Update

1 June 2023



This presentation and other related material may contain a number of "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding HOOKIPA's expectation about any or all of the following: (i) the success, cost and timing of HOOKIPA's product development activities and clinical trials; (ii) the timing, scope or likelihood of regulatory filings and approvals, including timing of Investigational New Drug Application and Biological Licensing Application filings for HOOKIPA's current and future product candidates, and final U.S. Food and Drug Administration, European Medicines Agency or other foreign regulatory authority approval of HOOKIPA's current and future product candidates; (iii) HOOKIPA's ability to develop and advance its current product candidates and programs into, and successfully complete, clinical studies; (iv) HOOKIPA's manufacturing, commercialization and marketing capabilities and strategy; (v) the potential benefits of and HOOKIPA's ability to maintain its collaboration with Gilead Sciences, Inc., and establish or maintain future collaborations or strategic relationships or obtain additional funding; (vi) risks relating to business interruptions resulting from the coronavirus (COVID-19) disease outbreak or similar public health crises and other matters that could affect the sufficiency of existing cash to fund operations and HOOKIPA's ability to achieve the milestones under the agreement with Gilead; and (vii) the rate and degree of market acceptance and clinical utility of HOOKIPA's current and future product candidates. Forward-looking statements can be identified by terms such as "believes," "expects," "plans," "potential," "would" or similar expressions and the negative of those terms HOOKIPA has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that it believes may affect its business, financial condition and results of operations. Although HOOKIPA believes that such statements are based on reasonable assumptions, forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond HOOKIPA's control, you should not rely on these forward-looking statements as predictions of future events. These risks and uncertainties include, among others: outcomes of HOOKIPA's planned clinical trials and studies may not be favorable; that one or more of HOOKIPA's product candidate programs will not proceed as planned for technical, scientific or commercial reasons; availability and timing of results from preclinical studies and clinical trials; uncertainty about regulatory approval to conduct clinical trials or to market a products; uncertainties regarding intellection property protection; and those risk and uncertainties described under the heading "Risk Factors" in HOOKIPA's Annual report on Form 10-K filed with the U.S. Securities and Exchange Commission on March 15, 2023 and in any other subsequent filings made by HOOKIPA with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. Existing and prospectus investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. HOOKIPA disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this presentation, other than to the extent required by law. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Today's presenting team





Joern Aldag Chief Executive Officer



Katia Schlienger Chief Medical Officer



Reinhard Kandera Chief Financial Officer



Klaus Orlinger Chief Scientific Officer

Building a Pipeline for the Novel Arenaviral Vector Technology Platform: Pioneer product HB-200 nearing registrational trial as a combination-therapy



	Indication	Preclinical	Phase 1	Phase	e 2 Phase 3
Oncoviral antigens HB-200*	HPV16+ HNSCC	1L Pembrolizumab Co 2L+ Monotherapy & P	ombination embrolizumab Combinatio	n	Planned registrational trial
 HB-200 means 2-vector thera application of HB-201 = LCN encoding HPV16 E6/E7 antig 	IV, HB-202 = PICV vectors,				

Pipeline for the Novel Arenaviral Vector Technology Platform: The platform is scalable in oncology space across multiple antigen classes



	Indication	Preclinical Phase 1	Phase 2 Phase 3
HB-200	HPV16+ HNSCC	1L Pembrolizumab Combination 2L+ Monotherapy & Pembrolizumab Combi	Planned registrational trial
Self antigens HB-300	Prostate cancer	Phase 1	

Pipeline for the Novel Arenaviral Vector Technology Platform: In partnership with Roche the platform is targeted to neo-antigens for mutKRAS



	Indication	Preclinical	Phase 1	Phase 2	Phase 3
HB-200	HPV16+ HNSCC	1L Pembrolizumab 2L+ Monotherapy &	Combination Pembrolizumab Combinatio		Planned registrational trial
HB-300	Prostate cancer	Phase 1			
Neo-antigens					
HB-700	^{Mut} KRAS tumors	Roche			

Pipeline for the Novel Arenaviral Vector Technology Platform: In partnership with Gilead, HOOKIPA is advancing functional cures for HBV and HIV



	Indication	Preclinical Pha	nse 1 F	Phase 2	Phase 3
HB-200	HPV16+ HNSCC	1L Pembrolizumab Combination 2L+ Monotherapy & Pembrolizuma	b Combination	Planned re	gistrational trial
HB-300	Prostate cancer	Phase 1			
HB-700	^{mut} KRAS tumors	Roche			
Infectious disease HB-400	HBV	🖉 GILEAD			
Infectious disease HB-500	HIV	🕼 GILEAD			

HB-200 Development Program:

Fundamental questions answered positively, unlocking potential of platform



HB-200 + Pembrolizumab is potentially more effective than Pembro alone	\checkmark	 HB-200 + pembrolizumab combination doubles ORR in 1st line ORR 43% vs. pembrolizumab 19%*
HB-200 is clinically active alone	~	 Clinical responses in monotherapy in CPI resistant patients Monotherapy shows preliminary mOS 14.2 mo. (ITT pop.)
HB-200 is driving expected T cell biology	~	 Unprecedented tumor-specific CD8+ T cells HB-200 induced T cell infiltration in tumors associated with clinical benefit
HB-200 shows favorable safety profile	~	 Favorable safety profile from over 130 patients In monotherapy and in combination

HB-200 Development Program:

The totality of the data support progression into a pivotal study



HB-200 + Pembrolizumab is potentially more effective than Pembro alone

HB-200 is clinically active alone

HB-200 is driving expected T cell biology

HB-200 shows favorable safety profile



Preparations for Pivotal 1st Line HNSCC Trial

Evaluation of additional development opportunities

HB-200 Phase 1/2: 132 patients enrolled as of March 31, 2023



Phase 1 Monotherapy HPV16+ HNSCC Dose Escalation & RP2D Confirmation	2L-6L 2-vector therapy 11 patients at optimal dose	2L and later lines 2-vector therapy 18 patients added	2L and later lines 2-vector therapy 12 patients at other doses	2L and later lines 1-vector therapy 20 patients	Non-HNSCC HPV+ tumors 1/2-vector therapy 32 patients
N=93	Follow-up data	Data developing			
Phase 2 Pembrolizumab Combination	1L Safety run-in 1-vector therapy	1L 2-vector therapy	2L+ Safety run-in 1-vector therapy	2L-7L 2-vector therapy	
HPV16+ HNSCC		14 patients evaluable		5 patients evaluable	
N=39		20 treated		15 treated	

• Preliminary Data: Includes unmonitored and unverified data based on current EDC data or data provided by Investigators. Data is subject to change.

• H 200-001 (NCT04180215)

HOOKIPA Pharma

Data reported today




11/1

• HB-200 + Pembrolizumab combination doubles ORR of Pembrolizumab in 1st line

HB-200 + Pembrolizumab as 1L Treatment Shows 43% ORR All responses confirmed under RECIST 1.1






Data cut-off 31-Mar-2023; 14 oropharynx cancer patients evaluable from 15 with at least 3 mo. follow up (\geq 2 scans); median follow-up 5.6 mo Responses assessed by RECIST v1.1 per investigator assessment; RECIST: Response Evaluation Criteria in Solid Tumors; SOD: Sum of diameters of target lesions

Preliminary Data: Includes unmonitored and unverified data based on current EDC data. Data is subject to change. ORR= Objective Response Rate; DCR= Disease Control Rate; CR=Complete Response; PR=Patrial Response; SD=Stable Disease; PD=Progressive Disease Pembrolizumab 1L: ORR: 19 % DCR: 47 %¹

1 Harrington Updated Data KEYNOTE-048 JCO 2023

HB-200 + Pembrolizumab 1st Line Sustained responses in majority of patients





- Shows Trends toward Durable Responses and Prolonged Disease Control
- mPFS not reached
- mOS not reached

Data cut-off 31-Mar-2023; 14 oropharynx cancer patients /20 treated with HB-202/HB-201 + pembrolizumab in the 1L setting evaluable for efficacy (at least ≥ 2 scans); median follow-up 5.6 mo Responses assessed by RECIST v1.1 / iRECIST per investigator assessment; RECIST: Response Evaluation Criteria in Solid Tumors, iRECIST: immune RECIST; SOD: Sum of diameters of target lesions Preliminary Data: Includes unmonitored and unverified data based on current EDC data. Data is subject to change.


HB-200 + Pembrolizumab Demonstrate Durable Response and Tumor **Reduction in Lung Lesions – Patient 1**



Patient 1:

- 67-year-old male •
- HPV16+ oropharynx cancer • (CPS 1)
- Refractory to platinum-based • chemoradiation (< 3 months)
- **Response**: PR in lung • metastases at 5 months
- Status: Ongoing treatment at • 10 months

Lung, lower right



Lesion disappeared












HB-200 + Pembrolizumab Demonstrate Durable Response and Tumor Reduction in Lung Lesions – Patient 2



Patient 2:

- 75-year-old male
- HPV16+ oropharynx cancer (CPS 86)
- 1L setting
- Response: rapid response in lung metastases since Week 6
- **Status**: Ongoing treatment at 4.5 months





Preliminary Data: Includes unmonitored and unverified data based on current EDC data. Data is subject to change. HOOKIPA Pharma




11/1

- HB-200 + Pembrolizumab combination doubles ORR of Pembrolizumab in 1st line
- Activity in 2nd Line+ (combination and monotherapy)


HB-200 Activity in 2nd Line+ in Combination with Pembrolizumab





Data cut-off 31-Mar-2023; 5/14 oropharynx cancer patients treated with HB-200 + pembrolizumab in the 2L and later line setting evaluable for efficacy (at least ≥ 2 scans); median follow-up 4.2 mo Responses assessed by RECIST v1.1 : Response Evaluation Criteria in Solid Tumors; SOD: Sum of diameters of target lesions Preliminary Data: Includes unmonitored and unverified data based on current EDC data. Data is subject to change.

HB-200 Phase 1 Monotherapy Follow-up in 2nd Line+ Preliminary mOS: 14.2 Months



HOOKIPA


- Monotherapy activity supports HB-200 potential in combinations
- mOS not reached in evaluable patients
- Preliminary Median Overall Survival (mOS): 14.2 Months

Update on Initial Cohort of HB-200 in Monotherapy

Data cut off 31 Mar 2023. Survival follow-up for 11 ITT (intent-to-treat) patients who received HB200 monotherapy at the same doses moved forward to Phase 2. Median follow-up: 12.8 mo (range 1.4-21.7 mo). Preliminary Data: includes unmonitored and unverified data based on current EDC data. Data is subject to change.

HB-200 Monotherapy: 2 Case Studies





Case 1:

- 65-year-old male with HPV16+ oropharynx cancer •
- Prior treatment: pembrolizumab + lenvatinib
- **Response:** PR -33% in lung lesion 5 months into treatment
- Status: Discontinued treatment at 8 months, surgical resection of lung lesion at 10 months. No residual tumor. Ongoing longterm follow-up at 22 months

Case 2:

- 75-year-old male with HPV16+ oropharynx cancer
- Prior treatment: 4 lines of therapy, incl. Chemo and CPI
- **Response:** near PR -29% in lung metastases after 2.6 months
- Status: Continued on HB-200 monotherapy until progression after over 11 months of therapy; added pembrolizumab per protocol and remains on study at 20 months.

Patient 1




11/1

- HB-200 + Pembrolizumab combination doubles ORR of Pembrolizumab in 1st line
- Activity in 2nd Line+ (combination and monotherapy)
- Highly functional T cell response associated with clinical benefit

HB-200 Monotherapy: Unprecedented CD8+ T cell Response





Direct measurement of T cells without prior in vitro expansion of cells (all HNSCC patients treated with 2 vector therapy Q3W)

¹HB200 two vector therapy mediated fold increase (max response on treatment vs before treatment) of systemic HPV-16 E7 and E6 specific T cells measured by ELISPOT;

²HPV-16 E6 and E7 specific CD8+ (killer) T cells out of total CD8+ T cells measured by intracellular cytokine staining;

HB-200 Monotherapy: T cell longevity and polyfunctionality






T cell kinetics by ELISPOT & analysis of IFN-g, IL-2, TNF-a and CD107a cytokine expression by intracellular cytokine staining at indicated timepoints

Pie charts indicate the percentage of tumor specific T cells expressing various numbers of cytokines (mean of all patients at indicated timepoints)

1 Polyfunctionality is the ability of T cells to carry out multiple functions simultaneously at the single cell level; The appearance of polyfunctional CD8+ effector cytotoxic T cells in vivo has been demonstrated to be a critical determinant of the success of immunological control of tumors (Imai N et al 2009, Yuan J et al 2008);

HB-200 Monotherapy – Association between T cell Induction and Clinical Outcome





Analysis of all available paired tumor biopsies from Phase I monotherapy study; Bars represent median increase (% change) of tumor infiltrating CD8+ T cells during therapy

(i.e. 1 & 2 vector therapy, different administration (IV & IT), different tumor sites (Oropharyngeal; anal, cervical))

SD: Stable disease; PD: Progressive disease; C3D1: day 1 of third administration cycle

- Association Between HB-200
 Induced CD8+ T Cells in
 Tumors and Clinical Benefit
 In Patients
- Greater CD8+ T cell
 infiltration observed in those
 with stable disease



11/1

- HB-200 + Pembrolizumab combination doubles ORR of Pembrolizumab in 1st line
- Activity in 2nd Line+ (combination and monotherapy)
- Highly functional T cell response associated with clinical benefit
- Favorable safety profile from over 130 patients

HB-200 Monotherapy and Combination

Serious adverse events related to treatment:

Treatment related-adverse events leading

to dose reduction or discontinuation: 2% of

Preliminary Data: Includes unmonitored and unverified data based on current EDC data.

Favorable safety profile across 132 patients in all settings

 Data suggest that Arenaviral therapies can safely be added to any other immunotherapy requiring more antigen-specific T

No death related to treatment

7% of patients

patients

cells

Data as of 31-Mar-23

Data is subject to change.

•

•

•

()		
Any event	HB-201 73 (55%) HB-202 68 (52%) Pembrolizumab 25 (64%)	125 (95%
Grade ≥3	17 (13%)	59 (45%)
Serious	9 (7%)	43 (33%)
Leading to dose reduction	2 (2%)	2 (2%)
Leading to discontinuation	3 (2%)	16 (12%)
Deaths	0	7 (5%)

Treatment related

adverse events*

All participants

(N=132)

 HB-200 means 2-vector therapy with alternating application of HB-201 = LCMV, HB-202 = PICV vectors, encoding HPV16 E6/E7 antigens




All adverse events



11/1

- HB-200 + Pembrolizumab combination doubles ORR of Pembrolizumab in 1st line
- Activity in 2nd Line+ (combination and monotherapy)
- Highly functional T cell response associated with clinical benefit
- Favorable safety profile from over 130 patients
- Preparing randomized trial with registrational intent

Development Opportunities For HB-200 in HPV+ HNSCC



HOOKIPA Pharma

HB-200 Development Program:

The totality of the data support progression into a pivotal study



HB-200 + Pembrolizumab is potentially more effective than Pembro alone

HB-200 is clinically active alone

HB-200 is driving expected T cell biology

HB-200 shows favorable safety profile



Preparations for Pivotal 1st Line HNSCC Trial

Evaluation of additional development opportunities



